Nurix CFO Hans van Houte sells $74,562 in shares

Hans van Houte, Nurix Therapeutics' CFO, divested $74,562 worth of the company's stock on November 4, 2026, according to an SEC filing. The sales were made using a pre-approved trading plan, with shares sold at prices between $15.3824 and $16.2018. Two separate transactions accounted for the sale, one involving 3,300 shares at an average price of $15.3824 per share and the other 1,469 shares at a weighted average price of $16.2018 per share.

Post-sale, van Houte still owns 42,745 shares of Nurix Therapeutics. The stock currently trades at $15.95, marking a 41% decrease over the past week. Despite this volatility, Nurix maintains a favorable financial health score and appears undervalued in InvestingPro's analysis. The company's recent quarterly report showcased strong results, including a net gain of $4.73 per share and $673.1 million in revenue from collaborations and licenses.

This performance earned the biotech firm a higher price target from H.C. Wainwright and an increase from Stifel, both expressing optimism about the company's prospects. However, Nurix faces challenges, such as Sanofi discontinuing a Phase 1 trial of SAR448272, which may impact future earnings. Despite these setbacks, other analysts remain bullish, with Wells Fargo and Jefferies lowering their price targets but retaining a positive outlook.